Solmux

Quick links to important sections

Solmux

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solmux

Quick Facts

Property Description
Active ingredient Carbocysteine (S-Carboxymethyl-L-cysteine)
Form Oral preparations (Syrup, liquid, capsules, tablets)
Pharmacological class Mucolytic agent (Mucoactive agent)
General purpose Facilitating the clearance of thickened mucus
Origin Synthetic derivative of L-cysteine

Defining the Active Ingredient and Pharmacological Class

Solmux is the well-known trade name for a medicine containing the active ingredient Carbocysteine, which is the non-proprietary name (INN) for S-Carboxymethyl-L-cysteine. Carbocysteine is classified as a mucolytic agent, placing it within the broader category of mucoactive agents that manage respiratory secretions. This compound is a synthetic derivative of the naturally occurring amino acid L-cysteine. Carbocysteine acts by altering the physical properties of respiratory secretions.

Composition and Forms: An Oral Therapeutic Agent

The active ingredient, Carbocysteine, is designed for the oral route of administration, making it a systemic treatment delivered through the digestive tract. The main dosage form(s) available under the Solmux brand include syrup, liquid, capsules, and tablets, which are often tailored for different patient demographics. The composition features Carbocysteine as a single-ingredient product in its primary formulations, alongside suitable excipients—such as an aqueous or non-aqueous liquid vehicle for syrup, or a solid excipient matrix for solid dosage forms. Furthermore, the Solmux portfolio occasionally includes specialized combination preparations.

The General Purpose of Solmux: Facilitating Mucus Clearance

The general purpose of Solmux is to help patients effectively manage and clear excessive and thickened mucus or phlegm from the respiratory tract. This is achieved through its core function: reducing the viscosity of mucus, making the secretions thinner and more fluid. This mechanism principle supports the body's natural system of mucociliary apparatus clearance, enabling the natural sweeping action to function more efficiently. This action is typically leveraged in scenarios where persistent, thick secretions are causing difficulty in breathing or comfortable expectoration.

What side effects are possible with Solmux?

Possible Side Effects and Safety Information

The safety profile for Carbocysteine (Solmux) is based on the classification and reporting standards defined by government regulatory documents. Adverse reactions are grouped by the physiological system they affect and their documented frequency.


Documented Adverse Reactions

Adverse effects are primarily associated with Gastrointestinal disorders and Skin and subcutaneous tissue disorders.

System-Organ Class Common Adverse Reactions Rare / Very Rare Adverse Reactions
Gastrointestinal disorders Nausea, Vomiting, Diarrhoea Gastrointestinal bleeding
Skin and subcutaneous tissue disorders Allergic skin rash, Urticaria, Pruritus Stevens-Johnson Syndrome (SJS), Erythema multiforme, Fixed drug eruption
Nervous system disorders Headache, Dizziness Rare (specific frequency varies)

The official labeling notes that some gastrointestinal effects may occur more frequently or intensely at high doses.


Serious Adverse Reactions and Safety Restrictions

Serious Adverse Reactions: Rare, but clinically significant, adverse events documented in regulatory sources include Gastrointestinal bleeding and severe cutaneous reactions classified as Bullous Skin Disorders, such as Stevens-Johnson Syndrome (SJS). Anaphylactic reactions are also documented as a rare event.

Safety Restrictions: The use of Carbocysteine is subject to specific safety constraints detailed in regulatory documents. It is contraindicated for use in individuals with known hypersensitivity to the active substance or in patients with active peptic ulceration due to the documented risk of gastrointestinal bleeding. Use is generally not recommended during the first trimester of pregnancy due to insufficient data.

Overdose and Emergency Response

Overdose and When to Seek Help

This information on Carbocysteine (Solmux) overdosage is derived exclusively from authoritative government regulatory documentation, such as the Summary of Product Characteristics (SmPC).

Documented Overdose Manifestations

The officially documented clinical presentation of an overdosage is defined by severe gastrointestinal disturbance, cited as the most likely symptom. This distress profile includes specific symptoms like nausea, vomiting, diarrhea, and gastralgia (stomach discomfort). Regulatory labels primarily confirm effects on the gastrointestinal system; they do not explicitly list severe systemic effects, such as cardiovascular or neurological complications, as direct manifestations of Carbocysteine overdosage.

Required Emergency Actions

Urgent medical attention must be sought immediately for a suspected overdose to ensure the initiation of required procedures. The official prescribing information mandates specific supportive measures be implemented by a healthcare professional. Treatment is focused on providing appropriate symptomatic treatment to manage the manifestations of gastrointestinal distress. Regulators state that gastric lavage may be beneficial in certain circumstances. Following initial management, a period of clinical observation is required to monitor the patient's recovery. Importantly, no specific pharmacological antidote is described in the official regulatory documentation for Carbocysteine overdosage.

Therapeutic Uses of Solmux

Quick Facts

  • Targeted Conditions: Respiratory tract disorders associated with excessive or thick mucus
  • Primary Benefit: Helps to reduce mucus viscosity for easier expectoration

Solmux, which contains the active ingredient carbocisteine, is a therapeutic option used as an adjunctive treatment for certain respiratory tract conditions. Its primary role is to act as a mucolytic agent.

This medication is used to support the management of disorders characterized by excessive or viscous (thick and sticky) mucus, such as acute bronchitis. By promoting changes in the properties of the mucus, the drug may help make the phlegm less thick and therefore easier for the patient to cough up and expel.

Additionally, carbocisteine may be indicated to assist in the management of exacerbations associated with chronic obstructive airways disease (COAD), which is also known as chronic obstructive pulmonary disease (COPD). It is important to note that this agent is intended to aid in mucus clearance, which is a common therapeutic goal in these disorders.

Regulatory References

  1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility Status for Solmux (Carbocysteine)

The regulatory documents for Carbocysteine strictly define eligibility based on patient population and pre-existing conditions, classifying use as contraindicated, not recommended, or requiring caution.

Absolute Contraindications

The medicine is strictly contraindicated and must not be used by specific populations. These absolute exclusions include:

  • Individuals with active peptic ulceration (stomach or duodenal ulcers).
  • Anyone with known hypersensitivity to Carbocysteine or any of the product's excipients.
  • The medicine is contraindicated for use in children less than 2 years of age.

Restricted Use and Special Caution

Use is generally not recommended or requires caution in several other patient groups:

  • Pregnancy and Lactation: Carbocysteine is not recommended during pregnancy, particularly the first trimester, or while breastfeeding, due to insufficient safety data.
  • Age and Comorbidities: Caution is advised for the elderly and for patients with a history of gastroduodenal ulcers.
  • Metabolic Restrictions: Certain formulations may be restricted for individuals with rare hereditary conditions, such as specific forms of lactose or fructose intolerance, due to the excipients used.

Approved use is generally established for adults and children aged two years and older.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Solmux, which contains Carbocysteine, indicates that there are no known pharmacokinetic interactions with other medicinal products. This means the drug's metabolism and clearance pathways (such as CYP enzymes or drug transporters) are not documented to be significantly altered by co-administered medicines, nor does Carbocysteine alter their disposition.


Pharmacodynamic and Additive-Risk Interactions

Interaction constraints primarily arise from pharmacodynamic conflicts and additive risk profiles as documented by national health authorities.

  • Antitussive and Secretion-Drying Medicines: Co-administration with antitussive medicinal products (cough suppressants) or medicines that dry secretions (like anticholinergics) is officially not recommended. This restriction is due to pharmacodynamic antagonism that may lead to the potential for retention of secretions or airway obstruction.
  • Medicines Increasing Bleeding Risk: Caution is warranted when co-administered with medicines known to cause gastrointestinal bleeding, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), corticosteroids, or antiplatelet agents. This combination carries a documented additive risk of gastrointestinal hemorrhage. This caution applies especially to elderly patients and those with a history of gastroduodenal ulcers.

Other Substances

No interaction is officially documented with food or alcohol, and official labeling does not specify any mandatory timing or separation requirements for administration.

Mechanism of Action

The mechanism of Carbocysteine (Solmux) is defined by three interconnected pharmacodynamic actions that influence the properties and production of respiratory secretions.


Direct Action on Mucus Structure (Mucolysis)

This mechanism involves a direct physical alteration of the secretions already present in the airways. The drug acts as a modified thiol that engages the highly cross-linked disulfide bonds ( S-S) within the mucin glycoprotein network. By cleaving these structural bonds, the mechanism lowers the viscoelasticity (thickness and stickiness) of the mucus gel. This physical change facilitates the required fluid dynamics for mucociliary clearance.


Cellular Regulation of Secretion Quality (Mucoregulation)

This domain addresses the cellular control over new mucus production. Carbocysteine modulates the activity of key transferase enzymes, which are responsible for adding sugar groups to mucin proteins. This action influences the synthesis of less viscous sialomucins over more viscous fucomucins, thereby influencing the composition and reducing the intrinsic viscosity of future secretions.


Modulation of Airway Inflammation and Stress

The drug also engages cellular defense pathways, acting as a transcriptional modulator. It suppresses the activation of the pro-inflammatory NF-kappa B pathway, which influences the production of mediators associated with hypersecretion. Concurrently, it activates the protective Nrf2 pathway, increasing endogenous antioxidant defense mechanisms. This dual modulation influences the cellular pathways associated with the chronic production of excessive, thick secretions.

Dosage and Administration Information

How Solmux (Carbocysteine) is Used

The usage of Solmux, containing the active ingredient Carbocysteine, follows specific administration protocols. The medication is intended for oral administration, utilizing various forms such as capsules, tablets, and liquid/syrup preparations.


Standard Dosing and Frequency

Administration is structured into two main daily dose levels for adults and older adults:

Dosing Phase Daily Carbocysteine Dose Administration Principle
Initial Dose 2,250 mg total per day Administered in divided doses, typically three times daily (TDS)
Maintenance Dose 1,500 mg total per day Dose reduction is applied upon achieving a satisfactory response

Liquid and syrup forms require accurate measurement using a calibrated measuring device, and the container should be shaken prior to use. Carbocysteine may be taken with or without food.


Population-Specific Administration

Dosage is adjusted for the pediatric population according to age:

  • Children 6–12 years: The usual dose is 250 mg, administered three times daily.
  • Children 2–5 years: Dosing ranges from 62.5 mg to 125 mg, administered four times daily.

Usage of this medicine is contraindicated in children younger than two years of age.


Procedural Constraint

A critical restriction exists regarding use: Carbocysteine must not be administered concurrently with antitussive (cough suppressant) medicinal products, as their actions are pharmacologically contrary to the mucolytic objective. The overall treatment duration is determined by the required clinical course.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Solmux (Carbocysteine)


Studies for Managing COPD and Chronic Bronchitis Flare-ups

Carbocysteine was studied for its long-term use in adults with Chronic Obstructive Pulmonary Disease (COPD) or chronic bronchitis, which are conditions presenting with cycles of stability and flare-ups. The research examined whether continuous use over several months was studied to determine whether it was associated with changes in outcomes related to episodic or acute manifestations of the condition. These studies included large-scale, long-term Randomized Controlled Trials (RCTs) and subsequent Meta-Analyses which pool data from multiple trials.

Systematic reviews and meta-analyses reports described patterns of observation regarding the frequency of exacerbations between the Carbocysteine group and the control groups. Research also highlights changes measured during the study period related to overall health and quality of life. However, findings were mixed when researchers examined the measurement of long-term physiological outcomes, such as general lung function.


Studies for Short-Term Acute Respiratory Symptoms

Research has explored the use of Carbocysteine as a supportive measure during conditions associated with acute or disruptive episodes, such as acute bronchitis and other short-term respiratory tract infections characterized by thick mucus. The research examined patient-reported outcomes describing perceived discomfort, primarily focusing on how symptoms like cough and the ease of clearing mucus change over time.


Areas Where Research is Still Uncertain

One area of uncertainty is the precise measurement of physiological outcomes, specifically concerning lung function measurements (like FEV1), where findings were mixed across different studies. Comparative evidence is lacking to definitively understand how Carbocysteine's observed patterns differ from other treatment options for the same indications. For children (pediatric populations), data for certain groups remain insufficient, and specific warnings and safety information were identified in regulatory summaries for use in infants younger than two years.

Key Studies & References

  1. Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis
  2. Carbocisteine Teva 375mg capsules, hard - Summary of Product Characteristics (HPRA)
  3. Summary of Product Characteristics (Xtex 250 mg /5 ml oral solution - HPRA)

Frequently Asked Questions (FAQ)

Common questions about Solmux (FAQ)


Q: Can Solmux be taken at the same time as cold medicine?

A: The official product information advises against taking Carbocysteine with certain types of cold medicine. Specifically, it should not be combined with cough suppressants (antitussives) or medicines that may dry up secretions, such as certain anticholinergics.

This restriction is based on pharmacodynamic principles, as combining them may lead to the potential for the retention of secretions, which is noted in official warnings.


Q: Is it okay to drive after taking Solmux?

A: According to the official regulatory documents, there are no known or applicable effects of Solmux on your ability to drive or operate machinery. However, if documented side effects like dizziness occur, individuals should consider avoiding the operation of vehicles until the symptom resolves.


Q: Can I take Solmux if I have mild kidney issues?

A: Official information advises caution for individuals with a history of chronic kidney disease. This is noted because Carbocysteine, the active ingredient, is primarily eliminated from the body through the kidneys.


Q: How long does it typically take for Solmux to start working?

A: Official product information indicates that the active ingredient begins to work at a chemical level relatively quickly. However, the overall improvement in symptoms, such as easier mucus clearance, may take some time to become fully noticeable.


Q: Are there different strengths of Solmux?

A: Yes, official regulatory labeling describes different available strengths of the product, such as formulations containing 250mg and 500mg of Carbocysteine. These different strengths are described to support the administration requirements for adults and children.


Q: Can older adults use Solmux?

A: Solmux is generally permitted for use in older adults. However, caution is specifically recommended for older adults with a known history of gastroduodenal ulcers (stomach or duodenal ulcers), due to safety restrictions noted in the official product information.


Q: What if I forget to take a dose of Solmux?

A: Official administration instructions advise that if a dose is missed, it should be skipped if it is nearly time for the next scheduled one. Official guidance consistently states that patients should not take two doses at the same time to compensate for a missed dose.


Q: Why do some people say Solmux gives them an upset stomach?

A: The official safety labeling documents the possibility of common adverse effects relating to the digestive system, classified as Gastrointestinal disorders. These documented reactions include gastric pain, nausea, vomiting, and diarrhoea, which align with reports of an upset stomach.


Q: Is there a version of Solmux specifically for children?

A: Yes, official dosing instructions describe specific formulations for the pediatric population. The medicine is often available in forms such as liquid or syrup with specialized dosing instructions for children aged 2 years and older.


Q: Is Solmux recommended for dry cough or wet cough?

A: Carbocysteine is classified as a mucolytic agent, meaning its purpose is to thin and clear excessive and thickened mucus or phlegm. This action is generally utilized to manage the symptoms associated with a wet or productive cough.


Q: Where does the active ingredient in Solmux come from?

A: The active ingredient in Solmux, Carbocysteine, is defined in official sources as a synthetic derivative. It is chemically derived from the naturally occurring amino acid L-cysteine.


Q: Can Solmux cause headaches?

A: Official safety documents list headache as a documented adverse event. While adverse reactions are reported by frequency, headache is noted as a possibility, usually classified in the rare or very rare categories.


Q: Is Solmux considered a natural product?

A: Official documents clarify the chemical nature of the active ingredient. Carbocysteine is defined as a synthetic derivative, meaning it is chemically manufactured, even though its structure is related to the naturally occurring amino acid L-cysteine.


Q: If I have allergies, can I still take Solmux?

A: Official safety documentation advises that the medicine is strictly contraindicated (must not be used) if an individual has a known hypersensitivity (allergic reaction) to Carbocysteine or any of the inactive ingredients (excipients) in the product.


Q: What does 'expectorant' mean in the context of Solmux?

A: Carbocysteine is classified as a mucolytic-type mucomodifier rather than a traditional expectorant. The drug aids expectoration (the process of coughing up mucus) by targeting the mucus structure to reduce its viscosity (thickness and stickiness).


Q: Does Solmux interact with herbal supplements?

A: Regulatory safety guidance indicates that there is not enough information available to confirm whether combining Carbocysteine with complementary medicines or herbal remedies is safe. Regulatory sources advise that insufficient data exists to support concurrent use.


Q: Are there flavored versions of Solmux?

A: Yes, Solmux is available in oral liquid forms, such as syrups or solutions. These formulations typically contain suitable excipients and flavoring agents to make the medicine palatable, which supports use in pediatric populations.


Q: What is the shelf life of Solmux?

A: The specific shelf life for Solmux is documented in the product's official regulatory summary (SmPC). The stated shelf life varies depending on the product's specific formulation, with some examples being documented as 2 years and 6 months from the date of manufacture.


Q: What is the role of the Solmux active ingredient in the body?

A: The primary role of the active ingredient, Carbocysteine, is classified as a mucolytic-type mucomodifier. It works by targeting the mucus structure to reduce its viscosity (thickness), which assists the body in clearing the secretions through expectoration.


Q: Has Solmux been approved by major regulatory bodies like the FDA or EMA?

A: Official regulatory documentation for Carbocysteine, such as the Summary of Product Characteristics (SmPC), is issued by bodies like the European Medicines Agency (EMA) and various national health authorities. These documents confirm the drug’s regulatory status, approved uses, and safety profile in those regions.


Q: Are there any concerns about Solmux affecting the liver?

A: Official pharmacokinetic data indicates that the medicine undergoes a significant process in the liver, known as a 'first-pass effect'. However, regulatory adverse reaction tables do not list liver or hepatic disorders as a documented common or rare side effect associated with the drug.


Q: If I have diabetes, is Solmux safe for me to use?

A: Official warnings state that patients with diabetes mellitus should be aware of the sugar content in the liquid or syrup formulations of the medicine. Regulatory documents specify that these forms often contain sucrose, which is a factor to consider for patients managing blood sugar levels.


Q: Does Solmux interact with common contraceptives?

A: Regulatory safety guidance notes an indirect interaction concern. If a patient experiences severe diarrhoea, which is a possible side effect of Solmux, this can potentially affect the absorption and, therefore, the effectiveness of the oral contraceptive pill due to altered drug clearance.

How should Solmux be stored and disposed of?

Storage Requirements

To ensure product stability, official labeling requires Solmux (carbocisteine) to be stored under controlled conditions. The medicine must be kept out of the sight and reach of children.

Storage Condition
Store at a temperature not exceeding 30, C; some formulations require storage not above 25, C
Must be protected away from direct heat, light, and moisture
Keep the container tightly closed and in the original outer carton
Oral solution contents must be used within one month once opened
Do not use the medicine after the expiry date (EXP)

Disposal Instructions

Unused or expired Solmux must not be disposed of via wastewater or household waste. The patient must ask a pharmacist how to dispose of medicines no longer required, following established local regulation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solmux found in:

A-Z Index: